Niraparib - Janssen/Merck/GSK
Alternative Names: GSK-3985771; JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula; ZL 2306Latest Information Update: 19 Jul 2024
At a glance
- Originator Merck & Co
- Developer Bayer; Dana-Farber Cancer Institute; Emory University; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; GSK; Hunan Cancer Hospital; Janssen; Katholieke Universiteit Leuven; Massachusetts General Hospital; Medica Scientia Innovation Research; Merck & Co; Myriad Genetics; NeoGenomics; Novocure Limited; OncoQuest; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; Takeda; Tempus; TESARO; Thomas Jefferson University; University Health Network; University of Florida; University of Kansas Medical Center; University of Oklahoma; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center; University of Turin; University of Utah; ZAI Lab
- Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase III Breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
- Phase II Cervical cancer; Cholangiocarcinoma; CNS cancer; Endometrial cancer; Glioblastoma; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
- No development reported Ewing's sarcoma; Gastric cancer; Haematological malignancies
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from a phase II FLORA-4 trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Ovarian cancer were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 26 Mar 2024 GlaxoSmithKline terminates a phase II trial in Glioma (Recurrent) in the US (NCT05297864)